Preprints.org · Nov 9, 2026
Skeletal Lead from the Leaded Petrol Era and Its Potential Role in Neurodegenerative Disease: Hypothesis and Research Agenda
By Laidlaw MA, Mielke HW
The use of leaded petrol exposed entire populations to lead through contaminated air, soil and dust. People who grew up during the decades of high petrol lead emissions may retain part of that exposure in their skeletons. Bone remodeling releases stored lead into circulation, with the potential for increased release during menopause, lactation and other periods of accelerated resorption. Pregnancy can also mobilize skeletal lead and transfer it to the fetus. This paper examines whether continued exposure from bone contributes to neurological and systemic disease in later life and whether reducing bone resorption could lower that exposure. Longitudinal studies associate cumulative lead exposure with cognitive decline, and observational studies suggest links with dementia and amyotrophic lateral sclerosis (ALS). These studies leave unresolved how much risk is attributable to lead released from bone in later life. In a small within-person pilot, blood lead fell by approximately 20% among migrant participants during alendronate treatment, a prescription bisphosphonate medication used to prevent and treat osteoporosis and manage Paget's disease of bone, with isotope changes consistent with reduced skeletal lead release (Gulson et al., 2002). Romosozumab is an anabolic (bone-forming) agent and a sclerostin inhibitor (Wu et al, 2023). It works with a dual effect - it both stimulates new bone formation and decreases bone breakdown, suppresses bone resorption and stimulates bone formation, making its effect on circulating lead a testable hypothesis. We propose a controlled study in adults with a clinical indication for osteoporosis treatment and directly measured skeletal lead. The initial endpoint should be a sustained change in circulating lead, with isotope evidence of reduced skeletal contribution where feasible. Trials of disease prevention would require evidence that the exposure reduction is durable and large enough to plausibly affect clinical risk.
doi.org/10.20944/preprints202611.0877.v1Open accessInterventions